CN113056456B - Tyk2激酶抑制剂 - Google Patents

Tyk2激酶抑制剂 Download PDF

Info

Publication number
CN113056456B
CN113056456B CN201980066166.4A CN201980066166A CN113056456B CN 113056456 B CN113056456 B CN 113056456B CN 201980066166 A CN201980066166 A CN 201980066166A CN 113056456 B CN113056456 B CN 113056456B
Authority
CN
China
Prior art keywords
compound
tyk2
compounds
disease
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980066166.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113056456A (zh
Inventor
J·C·里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sareum Ltd
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of CN113056456A publication Critical patent/CN113056456A/zh
Application granted granted Critical
Publication of CN113056456B publication Critical patent/CN113056456B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980066166.4A 2018-10-08 2019-10-07 Tyk2激酶抑制剂 Active CN113056456B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816369.1 2018-10-08
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds
PCT/EP2019/077118 WO2020074461A1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors

Publications (2)

Publication Number Publication Date
CN113056456A CN113056456A (zh) 2021-06-29
CN113056456B true CN113056456B (zh) 2023-06-13

Family

ID=64397425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980066166.4A Active CN113056456B (zh) 2018-10-08 2019-10-07 Tyk2激酶抑制剂

Country Status (18)

Country Link
US (1) US12187716B2 (enExample)
EP (1) EP3864009B1 (enExample)
JP (1) JP7383030B2 (enExample)
KR (1) KR102844196B1 (enExample)
CN (1) CN113056456B (enExample)
AU (1) AU2019359320B2 (enExample)
BR (1) BR112021006424A2 (enExample)
CA (1) CA3111049A1 (enExample)
DK (1) DK3864009T3 (enExample)
ES (1) ES3021420T3 (enExample)
FI (1) FI3864009T3 (enExample)
GB (1) GB201816369D0 (enExample)
IL (1) IL281599B2 (enExample)
MX (1) MX2021003929A (enExample)
PL (1) PL3864009T3 (enExample)
PT (1) PT3864009T (enExample)
SG (1) SG11202102490TA (enExample)
WO (1) WO2020074461A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796038A (zh) * 2007-05-10 2010-08-04 萨勒姆有限公司 *唑酪氨酸激酶抑制剂
EP2634185A1 (en) * 2012-03-02 2013-09-04 Sareum Limited TYK2 kinase inhibitors
CN105793245A (zh) * 2013-09-03 2016-07-20 萨勒姆有限公司 药物化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
NZ522696A (en) 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
MXPA03003868A (es) 2000-10-30 2003-07-28 Janssen Pharmaceutica Nv Inhibidores de tripeptidil peptidasa.
EP1554269A1 (en) 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
EP1932833B1 (en) 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
ATE480525T1 (de) 2006-05-12 2010-09-15 Ab Science Neues verfahren zur synthese von 2- aminooxazolverbindungen
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
EP2166846B1 (en) 2007-06-20 2012-10-17 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CA2730010A1 (en) 2008-07-09 2010-01-14 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
JP2013522267A (ja) 2010-03-17 2013-06-13 エフ．ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物、および使用法
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2013055645A1 (en) 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
AU2013341186B2 (en) 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
JP6310767B2 (ja) 2014-05-13 2018-04-11 日本電子株式会社 自動分析装置及びノズル洗浄方法
NO2721710T3 (enExample) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796038A (zh) * 2007-05-10 2010-08-04 萨勒姆有限公司 *唑酪氨酸激酶抑制剂
EP2634185A1 (en) * 2012-03-02 2013-09-04 Sareum Limited TYK2 kinase inhibitors
CN105793245A (zh) * 2013-09-03 2016-07-20 萨勒姆有限公司 药物化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
选择性氮杂吲哚类JAK抑制剂的设计、合成及体外活性评价;常先磊;中国人民解放军军事医学科学院硕士学位论文;全文 *

Also Published As

Publication number Publication date
ES3021420T3 (en) 2025-05-26
CA3111049A1 (en) 2020-04-16
MX2021003929A (es) 2021-06-04
BR112021006424A2 (pt) 2021-07-06
GB201816369D0 (en) 2018-11-28
EP3864009B1 (en) 2025-02-19
PL3864009T3 (pl) 2025-04-22
CN113056456A (zh) 2021-06-29
FI3864009T3 (fi) 2025-03-24
KR102844196B1 (ko) 2025-08-07
US20210387981A1 (en) 2021-12-16
KR20210076036A (ko) 2021-06-23
US12187716B2 (en) 2025-01-07
JP7383030B2 (ja) 2023-11-17
PT3864009T (pt) 2025-04-23
DK3864009T3 (da) 2025-03-17
IL281599B1 (en) 2024-06-01
WO2020074461A1 (en) 2020-04-16
SG11202102490TA (en) 2021-04-29
IL281599A (en) 2021-05-31
JP2022514799A (ja) 2022-02-15
EP3864009A1 (en) 2021-08-18
IL281599B2 (en) 2024-10-01
AU2019359320A1 (en) 2021-03-18
AU2019359320B2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US11673870B2 (en) Pharmaceutical compounds
JP6239118B2 (ja) 医薬化合物
CN110191887B (zh) IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
EP3864009B1 (en) Tyk2 kinase inhibitors
JP7660135B2 (ja) Ｔｙｋ２阻害剤の結晶形態
RU2805932C2 (ru) Фармацевтические соединения
HK40048146B (en) Tyk2 kinase inhibitors
HK40048146A (en) Tyk2 kinase inhibitors
HK1226067B (zh) 药物化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant